TIS 0.00% 0.0¢ tissue therapies limited

Ann: Response to ASX Price Query, page-26

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 322 Posts.
    lightbulb Created with Sketch. 67
    or "Profit taking day". (Lord of war / warlord).

    Like this quote in CEO report, seems to be confirming sales estimates:

    "Sales of VitroGro® ECM in the UK and Europe can start quickly
    once CE Mark is granted. Initially sales will be handled by
    Company staff and some consultants who are already
    working for Tissue Therapies. Hiring of new permanent sales
    staff will proceed once CE Mark is granted.
    CE Mark is also accepted by many countries (excluding the
    USA) as sufficient regulatory approval for the submission of
    applications for sale and this forms part of the global rollout
    plan for VitroGro® ECM during 2015.
    Efficient, scalable, commercial production of VitroGro® ECM
    has been achieved and is ready for global supply.
    Chronic skin wounds, particularly diabetic and venous ulcers
    represent a large and rapidly growing global market for
    which there are currently no definitive treatments.
    The Company has had the benefit of the advice of a number
    of expert and influential wound care clinicians in the UK,
    Europe and elsewhere who are keen to use VitroGro® ECM as
    soon as it is approved for sale.
    Expert health economic analyses continue to produce strong
    data to support the use and reimbursement of VitroGro® ECM
    in the UK and Europe. This data is planned to be published
    closer to sales launch.
    All new data that has been developed reinforces the view that
    VitroGro® ECM has the potential to transform the treatment
    of chronic wounds. We look forward to the start of sales."
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.